other material
confidence high
sentiment negative
materiality 0.65
Entrada completes first two cohorts in Phase 1 for ENTR-601-44; US clinical hold remains
Entrada Therapeutics, Inc.
- Completed dosing of first and second cohorts in Phase 1 trial ENTR-601-44-101 in the UK.
- Data from Phase 1 trial expected in second half of 2024.
- FDA clinical hold on IND remains in effect; FDA declined to lift hold despite additional data.
- Company plans global development for exon 44 skipping amenable DMD patients.
- Cash runway expected through 2025.